tiprankstipranks
Advertisement
Advertisement
Arcus Biosciences discontinues Star-121 study with Gilead due to futility
PremiumThe FlyArcus Biosciences discontinues Star-121 study with Gilead due to futility
10d ago
Arcus Biosciences price target lowered to $47 from $49 at Leerink
Premium
The Fly
Arcus Biosciences price target lowered to $47 from $49 at Leerink
10d ago
Arcus Ends Key Lung Cancer Trials in Gilead Partnership Reset
Premium
Company Announcements
Arcus Ends Key Lung Cancer Trials in Gilead Partnership Reset
10d ago
Arcus Biosciences: Casdatifan’s Differentiated HIF-2α Profile Versus Belzutifan Supports High-Risk Buy Rating
PremiumRatingsArcus Biosciences: Casdatifan’s Differentiated HIF-2α Profile Versus Belzutifan Supports High-Risk Buy Rating
2M ago
Arcus Biosciences price target raised to $49 from $36 at Leerink
Premium
The Fly
Arcus Biosciences price target raised to $49 from $36 at Leerink
2M ago
Arcus Biosciences Highlights Casdatifan Momentum in Call
Premium
Company Announcements
Arcus Biosciences Highlights Casdatifan Momentum in Call
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100